Not available in the U.S.

FR
Close
FR

Information

The content of this site is reserved for healthcare professionals, in accordance with Law No. 2011-2012 of December 29, 2011 relating to strengthening the health safety of medicines and health products, including the implementing decree relating to the advertising.

By clicking on OK, you confirm that you are a healthcare professional.

ACCEPT
close

Spontaneous application form

    We use cookies to give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

    ACCEPT

    Publication in the BMJ of the Pilot Study on the cost-effectiveness of FreeO2 in patients with COPD acute exacerbations

    25What  is the FreeO2 value proposition for COPD exacerbation ?

    Minus 21% in hospital cost of care (at 180days).

    Thomas G Poder1,2, Christian R C Kouakou2, Pierre-Alexandre Bouchard3, Véronique Tremblay4, Sébastien Blais4, François Maltais3, François Lellouche3. Cost-effectiveness of FreeO2 in patients with chronic obstructive pulmonary disease hospitalised for acute exacerbations: analysis of a pilot study in Quebec. BMJ Open 2018;8:e018835. doi: 10.1136/bmjopen-2017-018835

     

    BACK TO PUBLICATIONS